Bavarian Nordic's smallpox vaccine wins EC approval

08/8/2013 | BioWorld (free content)

The European Commission granted Bavarian Nordic approval to market the third-generation smallpox vaccine Imvanex. The approval is a first for the Danish vaccine-maker. Imvanex, which is in late-stage development in the U.S., can be used by patients with HIV, atopic dermatitis and others with weakened immune systems.

View Full Article in:

BioWorld (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX